Evidence map›Paper›PMID 30594917›Full record

ArticleCancer biomarkers : section A of Disease markers2019

ADP-ribosylation factor-like 4C predicts worse prognosis in endometriosis-associated ovarian cancers.

Shiro Wakinoue, Tokuhiro Chano, Tsukuru Amano, Takahiro Isono, Fuminori Kimura, Ryoji Kushima, Takashi Murakami

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Implications of ADP-Ribosylation Factor-Like Protein 4C (ARL4C) in Human Neoplasia With Special Emphasis on Ameloblastoma: A Scoping Review.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shiro WakinoueDepartment of Obstetrics and Gynecology, Shiga University of Medical Science, Shiga 520 2192, Japan.
Tokuhiro ChanoDepartment of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga 520 2192, Japan.
Tsukuru AmanoDepartment of Obstetrics and Gynecology, Shiga University of Medical Science, Shiga 520 2192, Japan.
Takahiro IsonoCentral Research Laboratory, Shiga University of Medical Science, Shiga 520 2192, Japan.
Fuminori KimuraDepartment of Obstetrics and Gynecology, Shiga University of Medical Science, Shiga 520 2192, Japan.
Ryoji KushimaDepartment of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga 520 2192, Japan.
Takashi MurakamiDepartment of Obstetrics and Gynecology, Shiga University of Medical Science, Shiga 520 2192, Japan.
Shiga University of Medical Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndometrioid ovarian carcinoma and clear cell ovarian carcinoma are both classified as endometriosis-associated ovarian cancer (EAOC). Despite the high rates of recurrence and mortality of EAOC, no prognostic biomarkers have been determined. ADP-ribosylation factor-like protein 4C (ARL4C) has been reported to be involved in various tumor progression processes, but its clinical significance for predicting prognosis in EAOC cases has never been studied.

objectiveThe present study aimed to determine the clinical significance of ARL4C expression in EAOC prognosis.

methodsARL4C expression was semi-quantitatively evaluated via immunohistochemistry in 61 EAOC patients, and the correlations between ARL4C expression and clinicopathological data and survival were statistically analyzed.

resultsThirty-six (59%) cases had high levels of ARL4C, which was related to worse 5-year overall survival (OS) (log-rank test, p= 0.036). In multivariate Cox proportional hazard model, high ARL4C expression was a significantly independent predictive factor for worse 5-year OS (hazard ratio = 12.048, p= 0.0201) and 5-year PFS (hazard ratio = 8.130, p= 0.0036).

conclusionsARL4C is a biomarker for worse prognosis and a novel therapeutic target in EAOC.

Indexed as

ADP-Ribosylation FactorsAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, EndometrioidDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMiddle AgedNeoplasm StagingOvarian NeoplasmsPrognosisADP-Ribosylation FactorsARL4C protein, humanBiomarkers, TumorADP-ribosylation factor-like protein 4Cclear cell ovarian carcinomaendometrioid ovarian carcinomaendometriosis-associated ovarian cancer

Identifiers

PMID30594917
PMCPMC13082491
OpenAlexW2907150421

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.